Tags

Type your tag names separated by a space and hit enter

Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.
Vojnosanit Pregl. 2012 Dec; 69(12):1067-75.VP

Abstract

BACKGROUND/AIM

Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD.

METHODS

In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 < or = Hamilton Rating Scale for Depression (HDRS) < or = 23)] without dementia [(25 < or = Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)].

RESULTS

Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 microg/L.

CONCLUSION

Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted.

Authors+Show Affiliations

Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23424961

Citation

Kostić, Vladimir, et al. "Fluoxetine Does Not Impair Motor Function in Patients With Parkinson's Disease: Correlation Between Mood and Motor Functions With Plasma Concentrations of Fluoxetine/norfluoxetine." Vojnosanitetski Pregled, vol. 69, no. 12, 2012, pp. 1067-75.
Kostić V, Dzoljić E, Todorović Z, et al. Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanit Pregl. 2012;69(12):1067-75.
Kostić, V., Dzoljić, E., Todorović, Z., Mijajlović, M., Svetel, M., Stefanova, E., Dragasević, N., Petrović, I., Milosević, M., Kovacević, I., Miljković, B., Pokrajac, M., & Prostran, M. (2012). Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanitetski Pregled, 69(12), 1067-75.
Kostić V, et al. Fluoxetine Does Not Impair Motor Function in Patients With Parkinson's Disease: Correlation Between Mood and Motor Functions With Plasma Concentrations of Fluoxetine/norfluoxetine. Vojnosanit Pregl. 2012;69(12):1067-75. PubMed PMID: 23424961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. AU - Kostić,Vladimir, AU - Dzoljić,Eleonora, AU - Todorović,Zoran, AU - Mijajlović,Milija, AU - Svetel,Marina, AU - Stefanova,Elka, AU - Dragasević,Natasa, AU - Petrović,Igor, AU - Milosević,Milenko, AU - Kovacević,Ivan, AU - Miljković,Branislava, AU - Pokrajac,Milena, AU - Prostran,Milica, PY - 2013/2/22/entrez PY - 2013/2/22/pubmed PY - 2013/8/28/medline SP - 1067 EP - 75 JF - Vojnosanitetski pregled JO - Vojnosanit Pregl VL - 69 IS - 12 N2 - BACKGROUND/AIM: Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. METHODS: In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 < or = Hamilton Rating Scale for Depression (HDRS) < or = 23)] without dementia [(25 < or = Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. RESULTS: Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 microg/L. CONCLUSION: Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted. SN - 0042-8450 UR - https://www.unboundmedicine.com/medline/citation/23424961/Fluoxetine_does_not_impair_motor_function_in_patients_with_Parkinson's_disease:_correlation_between_mood_and_motor_functions_with_plasma_concentrations_of_fluoxetine/norfluoxetine_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -